IREDELL HEALTH SYSTEM

Arixtra Monitoring Protocol	
Approved by: Laura Rollings, PharmD, BCPS, BCGP	Last Revised/Reviewed Date: 06/2021
P&T Committee	Date: 04/2011

Policy

Arixtra will be monitored according to protocol to provide optimal dosing and to minimize the risk of adverse events.

Procedure

A baseline CBC and serum creatinine will be obtained prior to initiating therapy, if not done within the previous 24 hours. A CBC and serum creatinine will be ordered weekly thereafter while on Arixtra. Pharmacists may order labs, if needed.

The provider will be contacted if:

- the platelet count is less than 100,000/mm^3 or by more than 30% from baseline
- the hemoglobin drops 3 grams from baseline
- there are visible signs or suspicion of bleeding (neurological changes, joint pain, abdominal/flank pain, etc.)
- stool is positive for blood
- the patient has an indwelling epidural or intrathecal catheter
- the creatinine clearance (CrCl) is <30 mL/min
- the patient's weight is <50 kg for prophylactic doses.

Arixtra should not be used with indwelling epidural or intrathecal catheters due to increased risk of hematoma formation, and it should be used with caution in patients with CrCl 30-50 mL/min.

Reference:
GlaxoSmithKline Pharmaceuticals. Arixtra Injection package insert. March 2010.

INITIAL EFFECTIVE DATE: 10/2009
DATES REVISIONS EFFECTIVE: 02/2010, 04/2010, 04/2011
DATES REVIEWED (no changes): 01/2016, 08/2018, 06/2021